Virtu Financial LLC Buys New Position in TransMedics Group, Inc. (NASDAQ:TMDX)

Virtu Financial LLC bought a new stake in shares of TransMedics Group, Inc. (NASDAQ:TMDX) in the 3rd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm bought 2,778 shares of the company’s stock, valued at approximately $436,000.

Several other large investors have also bought and sold shares of TMDX. Raymond James & Associates boosted its stake in TransMedics Group by 152.4% during the second quarter. Raymond James & Associates now owns 23,444 shares of the company’s stock valued at $3,531,000 after buying an additional 14,156 shares in the last quarter. EFG Asset Management North America Corp. boosted its stake in TransMedics Group by 12.4% during the second quarter. EFG Asset Management North America Corp. now owns 21,196 shares of the company’s stock valued at $3,191,000 after buying an additional 2,343 shares in the last quarter. SlateStone Wealth LLC bought a new position in TransMedics Group during the second quarter valued at about $856,000. HB Wealth Management LLC purchased a new stake in shares of TransMedics Group during the second quarter valued at $318,000. Finally, F M Investments LLC purchased a new stake in shares of TransMedics Group during the second quarter valued at $10,957,000. Institutional investors own 99.67% of the company’s stock.

TransMedics Group Stock Down 2.2 %

Shares of TransMedics Group stock opened at $64.26 on Monday. The stock has a 50-day moving average price of $95.77 and a 200 day moving average price of $131.29. The company has a market cap of $2.16 billion, a P/E ratio of 68.36 and a beta of 2.06. The company has a current ratio of 8.20, a quick ratio of 7.33 and a debt-to-equity ratio of 2.42. TransMedics Group, Inc. has a 1 year low of $63.42 and a 1 year high of $177.37.

TransMedics Group (NASDAQ:TMDX) last issued its earnings results on Monday, October 28th. The company reported $0.12 earnings per share for the quarter, missing the consensus estimate of $0.29 by ($0.17). TransMedics Group had a return on equity of 18.74% and a net margin of 8.14%. The firm had revenue of $108.76 million during the quarter, compared to analyst estimates of $115.00 million. During the same period in the previous year, the company earned ($0.12) earnings per share. The business’s revenue for the quarter was up 63.7% on a year-over-year basis. As a group, analysts expect that TransMedics Group, Inc. will post 1 EPS for the current fiscal year.

Analysts Set New Price Targets

Several equities research analysts have recently commented on TMDX shares. TD Cowen reduced their target price on TransMedics Group from $175.00 to $120.00 and set a “buy” rating for the company in a report on Monday, November 18th. Robert W. Baird reduced their target price on TransMedics Group from $150.00 to $120.00 and set an “outperform” rating for the company in a report on Wednesday, December 11th. Piper Sandler reduced their target price on TransMedics Group from $110.00 to $90.00 and set an “overweight” rating for the company in a report on Wednesday, December 11th. JPMorgan Chase & Co. reduced their target price on TransMedics Group from $173.00 to $116.00 and set an “overweight” rating for the company in a report on Tuesday, October 29th. Finally, Baird R W raised TransMedics Group to a “strong-buy” rating in a report on Tuesday, September 24th. Two research analysts have rated the stock with a hold rating, eight have assigned a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average price target of $126.80.

Insiders Place Their Bets

In other TransMedics Group news, CEO Waleed H. Hassanein sold 8,625 shares of the company’s stock in a transaction dated Tuesday, October 15th. The stock was sold at an average price of $132.71, for a total value of $1,144,623.75. Following the transaction, the chief executive officer now directly owns 61,643 shares of the company’s stock, valued at $8,180,642.53. This represents a 12.27 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, Director Edward M. Basile sold 6,750 shares of the company’s stock in a transaction dated Tuesday, November 5th. The stock was sold at an average price of $83.55, for a total value of $563,962.50. Following the completion of the transaction, the director now directly owns 732 shares in the company, valued at approximately $61,158.60. The trade was a 90.22 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 19,417 shares of company stock valued at $2,240,738 in the last three months. Insiders own 7.00% of the company’s stock.

TransMedics Group Company Profile

TransMedics Group, Inc, a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body.